AMAG

Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h

SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)

SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)

SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)

WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors

LUXEMBOURG and ZUG, Switzerland, Nov. 16, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") today announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger. The combined organization will operate as part of the Covis Pharma Group and will be led by Covis CEO Michael Porter. The addition of AMAG's category leading treatments and development-stage assets in women's health and hematology/oncology supports the execution of Covis' strategic vision to enhance the company's ability to impact the lives of patients by expan

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AMAG to Covis Group S.à r.l. for $13.75 per share. If you are a AMAG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Contango Oil & Gas Company (NYSE: MCF) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MCEP to MCF. If you are a MCEP or MCF investor, and woul

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Virtusa Corporation (NASDAQ: VRTU) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds affiliated with Baring Private Equity Asia for $51.35 per share. If you are a Virtusa shareholder, click on this link to learn more about your rights and options:  https://halpersadeh.com/actions/virtusa-corporation-vrtu-stock-merger-baring-asia/. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sal

NEW YORK, Oct. 30, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AMAG to Covis Group S.à r.l. for $13.75 per share. If you are a AMAG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Eaton Vance Corp. (NYSE:EV) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of EV to Morgan Stanley. If you are a EV investor, and wo

NEW YORK, Oct. 29, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] Perceptron, Inc. (NASDAQ: PRCP) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Perceptron, Inc. (NASDAQ: PRCP) in connection with the proposed acquisition of the company by affiliates of Swedish-based Atlas Copco Group.  Under the terms of the agreement, PRCP shareholde

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) – URGENT-TENDER OFFER EXPIRES NOVEMBER 12, 2020. WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) in connection with the proposed acquisition of the company by Covis Group S.à r.l.  Under t

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: NTN Buzztime, Inc. (NYSE: NTN) A registration statement was recently filed with the SEC regarding Brooklyn ImmunoTherapeutics' acquisition of NTN.  Upon completion of the merger, shareholders of NTN will own between approximately 5.92% and 3.26% of the combined company.  The investigation conc

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Covis Group S.à r.l. for $13.75 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/amag-pharmaceuticals-inc-stock-merger-covis/. Virtusa Corporation (NASDAQ: VRTU) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds affiliated with Baring Private Equity Asia for $51.35 per

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AMAG to Covis Group S.à r.l. for $13.75 per share. If you are a AMAG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Eaton Vance Corp. (NYSE:EV) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of EV to Morgan Stanley. If you are a EV investor, and would like add

WILMINGTON, Del., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating AMAG Pharmaceuticals, Inc. (“AMAG”) (NASDAQ GS: AMAG) regarding possible breaches of fiduciary duties and other violations of law related to AMAG’s agreement to be acquired by Covis Group S.à.r.l. Under the terms of the agreement, AMAG’s shareholders will receive $13.75 per share in cash. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-amag-pharmaceuticals-inc. You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com. Rigrodsky & Long, P.A., with offices in Delaware and N

NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AMAG to Covis Group S.à r.l. for $13.75 per share. If you are a AMAG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. MobileIron, Inc. (NASDAQ GS: MOBL) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MOBL to Ivanti, Inc. for $7.05 per share. If yo

LUXEMBOURG and ZUG, Switzerland, Oct. 15, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") announced the commencement of a cash tender offer to purchase all of the outstanding shares of common stock of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) ("AMAG"). The tender offer is being made pursuant to the merger agreement (the "Merger Agreement") announced by Covis and AMAG on October 1, 2020 under which Covis has agreed to acquire AMAG for $13.75 per share. The transaction has a total enterprise value of approximately $647 million, including net debt. The $13.75 per share all-cash tender offer represents a premium of approximately 46% over AMAG's closing stock price on September 30, 2020, t

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) in connection with the proposed acquisition of the company by Covis Group S.à r.l.  Under the terms of the acquisition agreement, which is s

WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of Makena®, the only FDA-approved treatment, along with its equivalent generics, to reduce preterm birth. Makena was approved in 2011, based on the landmark NICHD MFMU trial by Meis et al. A second, FDA-required trial (PROLONG) predominantly enrolled women outside of the U.S., in countries with markedly lower rates of preterm birth. The PROLONG trial did not show a difference between treatment and vehicle arms with respect to preterm birth or

NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: GCI Liberty, Inc. (NASDAQ: GLIBA) A registration statement was recently filed with the SEC regarding Liberty Broadband Corporation Company’s acquisition of GCI Liberty. Upon completion of the merger, current shareholders of GCI Liberty will own approximately 16.7% of the combin

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AMAG to Covis Group S.à r.l. for $13.75 per share. If you are a AMAG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. MobileIron, Inc. (NASDAQ GS: MOBL) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MOBL to Ivanti, Inc. for $7.05 per share. If yo

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Covis Group S.à r.l. for $13.75 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/amag-pharmaceuticals-inc-stock-merger-covis/. Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its proposed merger with F-star Therapeutics, Limited. Under th

The product remains on the marketAMAG has 15 days to respond to the FDAAMAG continues to expect its recently announced tender offer and merger to close in November 2020 WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received a notice from the U.S. Food and Drug Administration (FDA) that the FDA is proposing to withdraw approval of Makena® (hydroxyprogesterone caproate injection), a treatment approved to reduce preterm birth in pregnant women who have had a prior spontaneous preterm birth. The FDA in its letter also notified AMAG that the company has the opportunity to request a hearing on the withdrawal. AMAG is evaluat

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AMAG Pharmaceuticals, Inc.  ("AMAG" or the "Company") (NASDAQ: AMAG) in connection with the proposed acquisition of the Company by Covis Group S.à r.l. ("Covis").  Under the terms of the acquisition agreement, which is structured as a tender offer, AMAG shareholders will be entitled to receive $13.75 in cash for each share of AMAG common stock that they own. If you own AMAG shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http://www.weissla